Ionis Pharmaceuticals (IONS) Stock Price, Quote & News

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat...

Industry: Biotechnology

Sector: Healthcare

Phone: 760 931 9200

Website: www.ionis.com

Address:

2855 Gazelle Court, Carlsbad, United States

trader_q Aug. 9 at 3:48 AM

$IONS after some readouts Zilganersen has 75–85% probability of FDA approval prior to PDUFA date of September 22, 2026.

1 · Reply

JuggernautRaider Aug. 5 at 6:12 PM

$IONS hmmm maybe

0 · Reply

johnnygogogo Aug. 5 at 3:37 PM

$IONS Tryngolza’s “first mover advantage” be like… @skeezbag $ARWR

2 · Reply

kb60521 Aug. 4 at 11:09 PM

$IONS Just ask Claude.ai or ChatGPT Share your views on IONS getting a positive response from FDA on Zilganersen

0 · Reply

Quantumup Aug. 4 at 11:37 AM

Canaccord Genuity y'day⬇️ $STOK to $58 from $60 and reiterated Buy after STOK reported its 2Q26 results. $BIIB PRAX DRUG HLUBF HLBBF $IONS HRMY OVID SUPN UCBJY JAZZ Here's what Canaccord Genuity said in its note to investors: https://x.com/Quantumup1/status/2084604516561756445?s=20

0 · Reply

CynthiaOreily777 Aug. 3 at 2:21 PM

$LTC $HGRAF $PENGU $IONS $AVAX Litecoin remains a leading payment cryptocurrency, HGRAF benefits from strategic mineral demand, PENGU depends on meme coin adoption, Ionis advances RNA therapies, and Avalanche expands its blockchain ecosystem.

0 · Reply

Toptradersam Aug. 3 at 9:20 AM

$PLTR $DIA $DIS $IONS $LKNCY 🎯 Think you're too old to become a successful trader? Experience, patience, and discipline can be powerful edges. Watch the full video! https://www.youtube.com/watch?v=zr8MZhrMn6o

0 · Reply

SecoTrader Aug. 3 at 9:04 AM

$IONS open market buy of 1$M!! by a Director is telling us where this is heading. Director’s salaries are not on the milloon dollar range per year, so this is definitely a very positive sign down the road. I have bought a significant amount of shares myself with an average of 56$ as we speak.

1 · Reply

djgestates Aug. 3 at 8:58 AM

$IONS

0 · Reply

Etiqute Aug. 3 at 8:39 AM

$IONS DAWNZERA and TRYNGOLZA—remain entirely uncompromised and are outperforming early launch projections.Insider Confidence: Highlighting that the asset base is fundamentally undervalued at current trading levels, Ionis Director Dr. Michael Hayden executed an aggressive $1.05 million open-market insider stock purchase at the end of July 2026.

0 · Reply

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

IONS

2026-08-03T11:37:37.000Z - 10 days ago

Ionis Pharmaceuticals price target raised to $76 from $72 at JPMorgan

IONS

2026-07-30T12:06:10.000Z - 14 days ago

Ionis Pharmaceuticals price target raised to $93 from $90 at BofA

IONS

2026-07-30T10:17:10.000Z - 14 days ago

Ionis Pharmaceuticals price target lowered to $115 from $125 at H.C. Wainwright

IONS

2026-07-29T21:45:20.000Z - 14 days ago

Ionis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs

IONS

Jul 29, 2026, 8:30 AM EDT - 15 days ago

Ionis Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 15 days ago

Ionis Pharmaceuticals Earnings release: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 15 days ago

Ionis Pharmaceuticals Slides: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 15 days ago

Ionis Pharmaceuticals Quarterly report: Q2 2026

2026-07-29T11:16:57.000Z - 15 days ago

Ionis Pharmaceuticals announces chief scientific officer Bennett to retire

IONS

2026-07-29T11:16:28.000Z - 15 days ago

Ionis Pharmaceuticals reports Q2 EPS (69c), consensus (88c)

IONS

Jul 29, 2026, 7:05 AM EDT - 15 days ago

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

IONS

Jul 29, 2026, 7:00 AM EDT - 15 days ago

Ionis reports second quarter 2026 financial results and highlights progress on key programs

IONS

Jul 28, 2026, 12:46 PM EDT - 15 days ago

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

IONS

Jul 23, 2026, 11:30 AM EDT - 20 days ago

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

IONS

2026-07-21T12:06:09.000Z - 23 days ago

Ionis Pharmaceuticals price target lowered to $89 from $106 at Guggenheim

IONS

2026-07-15T21:15:17.000Z - 4 weeks ago

Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research

IONS

Jul 15, 2026, 7:05 AM EDT - 4 weeks ago

Ionis to hold second quarter 2026 financial results webcast

IONS

Jul 14, 2026, 9:16 AM EDT - 4 weeks ago

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

IONS

2026-07-13T13:25:09.000Z - 4 weeks ago

Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital

IONS

2026-07-13T11:05:59.000Z - 4 weeks ago

Ionis Pharmaceuticals doses first participant in Phase 1-2 ASCEND study

IONS

Jul 13, 2026, 7:00 AM EDT - 4 weeks ago

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

IONS

2026-07-10T12:25:48.000Z - 4 weeks ago

Ionis Pharmaceuticals price target lowered to $110 from $130 at Morgan Stanley

IONS

2026-07-10T11:05:45.000Z - 4 weeks ago

Ionis Pharmaceuticals price target lowered to $95 from $110 at Canaccord

AZN IONS

Jul 9, 2026, 7:38 AM EDT - 5 weeks ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

ALNY AZN IONS

Jul 9, 2026, 5:53 AM EDT - 5 weeks ago

Major drugmaker loses $27 billion in market value after failed trial

AZN IONS

Jul 9, 2026, 2:12 AM EDT - 5 weeks ago

AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

AZN IONS

Jul 9, 2026, 2:00 AM EDT - 5 weeks ago

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

IONS

Jul 6, 2026, 7:00 AM EDT - 5 weeks ago

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

IONS

Jun 25, 2026, 2:59 AM EDT - 7 weeks ago

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

IONS

Jun 24, 2026, 3:30 PM EDT - 7 weeks ago

Ionis Pharmaceuticals Transcript: FDA announcement

Jun 24, 2026, 3:30 PM EDT - 7 weeks ago

Ionis Pharmaceuticals Slides: FDA announcement

Jun 24, 2026, 3:30 PM EDT - 7 weeks ago

Ionis Pharmaceuticals Press release: FDA announcement

Jun 24, 2026, 2:37 PM EDT - 7 weeks ago

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

IONS

Jun 10, 2026, 8:40 AM EDT - 2 months ago

Ionis Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 8:40 AM EDT - 2 months ago

Ionis Pharmaceuticals Slides: FY 2026

Jun 8, 2026, 7:00 AM EDT - 2 months ago

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

IONS

Jun 4, 2026, 5:30 PM EDT - 2 months ago

Ionis Pharmaceuticals Transcript: AGM 2026

Jun 4, 2026, 5:30 PM EDT - 2 months ago

Ionis Pharmaceuticals Slides: FY 2026

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

IONS

May 28, 2026, 4:45 AM EDT - 2 months ago

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

IONS

May 19, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 14, 2026, 7:05 AM EDT - 3 months ago

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

IONS

May 12, 2026, 1:40 PM EDT - 3 months ago

Ionis Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 4, 2026, 7:05 AM EDT - 3 months ago

Ionis to host 2026 virtual Annual Meeting of Stockholders

IONS

May 1, 2026, 7:05 AM EDT - 3 months ago

Ionis to present at upcoming investor conferences

IONS

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Ionis Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 7:00 AM EDT - 3 months ago

Ionis reports first quarter 2026 financial results and highlights progress on key programs

IONS

Apr 28, 2026, 2:06 AM EDT - 3 months ago

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

IONS

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Ionis Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Ionis Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

IONS

Apr 15, 2026, 7:05 AM EDT - 4 months ago

Ionis to hold first quarter 2026 financial results webcast

IONS

Mar 30, 2026, 7:30 AM EDT - 4 months ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

BIIB IONS

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

IONS

Mar 17, 2026, 12:00 PM EDT - 5 months ago

Ionis Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 1:30 PM EDT - 5 months ago

Ionis Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 9, 2026, 3:40 PM EDT - 5 months ago

Ionis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Ionis announces changes to Board of Directors

IONS

Mar 5, 2026, 7:30 AM EST - 5 months ago

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

BIIB IONS

Mar 2, 2026, 10:30 AM EST - 5 months ago

Ionis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 7:00 AM EST - 5 months ago

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

IONS

Feb 26, 2026, 12:00 PM EST - 5 months ago

Ionis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 7:00 AM EST - 6 months ago

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

IONS

Feb 25, 2026, 8:30 AM EST - 6 months ago

Ionis Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:30 AM EST - 6 months ago

Ionis Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:30 AM EST - 6 months ago

Ionis Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:30 AM EST - 6 months ago

Ionis Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 7:00 AM EST - 6 months ago

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

IONS

Feb 17, 2026, 2:58 PM EST - 6 months ago

Ionis updates time for fourth quarter and full year 2025 financial results webcast

IONS

Feb 11, 2026, 7:05 AM EST - 6 months ago

Ionis to hold fourth quarter and full year 2025 financial results webcast

IONS

Jan 21, 2026, 7:00 AM EST - 7 months ago

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

IONS

Jan 13, 2026, 11:15 AM EST - 7 months ago

Ionis Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 7 months ago

Ionis Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

IONS

Jan 7, 2026, 2:15 AM EST - 7 months ago

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

IONS

Jan 6, 2026, 7:05 AM EST - 7 months ago

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

IONS

Dec 2, 2025, 7:00 AM EST - 9 months ago

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

IONS

Dec 1, 2025, 7:00 AM EST - 9 months ago

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

IONS

Nov 18, 2025, 8:30 AM EST - 9 months ago

Ionis Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 4:05 PM EST - 9 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

BIIB IONS

Nov 14, 2025, 7:00 AM EST - 9 months ago

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

IONS

Nov 13, 2025, 8:00 AM EST - 9 months ago

Ionis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 12:39 AM EST - 9 months ago

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

IONS

Nov 11, 2025, 4:05 PM EST - 9 months ago

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

IONS

Nov 8, 2025, 3:00 PM EST - 9 months ago

Ionis Pharmaceuticals Transcript: Study Update

Nov 8, 2025, 3:00 PM EST - 9 months ago

Ionis Pharmaceuticals Slides: Study Update

Nov 8, 2025, 9:40 AM EST - 9 months ago

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

IONS

Nov 6, 2025, 8:00 AM EST - 10 months ago

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

IONS

trader_q Aug. 9 at 3:48 AM

$IONS after some readouts Zilganersen has 75–85% probability of FDA approval prior to PDUFA date of September 22, 2026.

1 · Reply

JuggernautRaider Aug. 5 at 6:12 PM

$IONS hmmm maybe

0 · Reply

johnnygogogo Aug. 5 at 3:37 PM

$IONS Tryngolza’s “first mover advantage” be like… @skeezbag $ARWR

2 · Reply

kb60521 Aug. 4 at 11:09 PM

$IONS Just ask Claude.ai or ChatGPT Share your views on IONS getting a positive response from FDA on Zilganersen

0 · Reply

Quantumup Aug. 4 at 11:37 AM

0 · Reply

CynthiaOreily777 Aug. 3 at 2:21 PM

0 · Reply

Toptradersam Aug. 3 at 9:20 AM

0 · Reply

SecoTrader Aug. 3 at 9:04 AM

1 · Reply

djgestates Aug. 3 at 8:58 AM

$IONS

0 · Reply

Etiqute Aug. 3 at 8:39 AM

0 · Reply

Etiqute Aug. 3 at 8:39 AM

$IONS Impact on Long-Term Consensus Stock ValuationsRecent Volatility Reset: The stock experienced a major correction in July 2026 (dropping over 20% to around $51.77) after its partnered Phase 3 trial with AstraZeneca (CARDIO-TTRansform for eplontersen in ATTR-CM) failed to meet its primary efficacy endpoint.Price Target Downgrades: Wall Street analysts reacted by trimming their long-term growth and profit margin models. The consensus average price target was recently revised down from roughly $104.00 to a range of $92.00 to $99.50.THE Bull Case Recovery: Despite the eplontersen setback, analyst sentiment remains highly constructive, holding a Strong Buy consensus with 20+ buy ratings and zero sells. Wall Street views the recent sell-off as overdone because Ionis’s wholly owned core commercial assets—

0 · Reply

Etiqute Aug. 3 at 8:38 AM

$IONS Imminent Clinical Trial ReadoutsPelacarsen (Lipoprotein(a) Lowering): Managed in partnership with Novartis, the landmark Phase 3 Lp(a)HORIZON cardiovascular outcomes trial is event-driven and explicitly targeted for a topline data readout in the second half of 2026. This study tracks over 8,000 patients and serves as the industry’s first major indicator of whether lowering Lp(a) levels clinically reduces heart attacks and strokes.Olezarsen / TRYNGOLZA (FCS Milestone): Following its baseline approvals, additional Phase 3 data cuts tracking long-term safety and broader efficacy parameters for familial chylomicronemia syndrome (FCS) are scheduled to be integrated into rolling regulatory packages throughout late 2026.

0 · Reply

Etiqute Aug. 3 at 8:33 AM

$IONS Partnered RoyaltiesCurrent Drivers: Ionis continues to generate stable streams from older assets, including $53 million in Q2 royalties from Biogen's Spinraza and a 60% year-over-year jump to $16 million from AstraZeneca's Wainua.

0 · Reply

Etiqute Aug. 3 at 8:23 AM

$IONS Wholly Owned Product Sales Forecasts (Full-Year 2026)DAWNZERA (Donidalorsen): Guided for $110 million to $120 million in full-year sales. It generated $26 million in Q2 2026 (up 63% sequentially from Q1) following its recent launch momentum and EU approvals for hereditary angioedema (HAE).TRYNGOLZA (Olezarsen): Guided for $100 million to $110 million in full-year sales. While Q2 sales dipped to $5 million due to a strategic wholesale price reset, the drug was recently approved for severe hypertriglyceridemia (sHTG), and management expects a sharp sales acceleration in H2 2026. Management reiterates long-term peak annual revenues of over $3 billion for Tryngolza.

0 · Reply

Etiqute Aug. 3 at 8:23 AM

$IONS Ionis Pharmaceuticals (IONS) has provided explicit guidance for its major near-term clinical launches and reaffirmed full-year 2026 product-level sales targets.Upcoming Product Launch & Regulatory DatesZilganersen (Alexander Disease): The FDA Priority Review PDUFA target action date is September 22, 2026. If approved, Ionis plans an immediate U.S. launch, marking its first independent commercial expansion into neurology. It out-licensed ex-U.S. commercial rights to Recordati in June 2026.Bepirovirsen (Chronic Hepatitis B): Partnered with GSK, this drug faces a PDUFA target action date on October 26, 2026, with launches anticipated in the U.S. and Japan shortly after approval.Obudanersen / ION582 (Angelman Syndrome): Fully enrolled its Phase 3 REVEAL study, with topline data expected in the second half of 2027.

0 · Reply

Etiqute Aug. 3 at 8:22 AM

$IONS Runway and Next MilestonesOperational Burn: Projected non-GAAP operating loss for 2026 is managed between $425 million and $475 million.Next Phase / Breakeven: The current liquidity cushion easily covers ongoing commercial drug launches (like DAWNZERA and TRYNGOLZA) and late-stage pipeline trials, keeping them secure on a clear path toward 2028 profitability.

0 · Reply

Etiqute Aug. 3 at 8:22 AM

$IONS Ionis Pharmaceuticals (ticker: IONS) reported $2.1 billion in cash, cash equivalents, and short-term investments as of June 30, 2026. Yes, this amount is widely projected by management and analysts to be more than enough to fund operations until the company reaches its targeted cash-flow breakeven in 2028.Cash and Financial PositionCurrent Balance: $2.1 billion (down from $2.7 billion at the end of 2025 due to planned debt repayment of convertible notes).Year-End Projections: Management expects to finish the year 2026 with over $1.6 billion in cash and investments.Revenue Guidance: Full-year 2026 revenue is guided between $875 million and $900 million.

0 · Reply

kb60521 Aug. 1 at 5:07 PM

$IONS Why is it so quiet here? is it because majority of the shares owned by insiders/institutions?

0 · Reply

FilingTracker Jul. 31 at 8:45 PM

$IONS Insider purchased $1.06 million worth of shares: https://filingtracker.ai/filing/874015/0000874015-26-000254

2 · Reply

trader_q Jul. 31 at 1:40 PM

$IONS hell is wrong with this stock no chance of going up.

1 · Reply

kb60521 Jul. 30 at 3:19 PM

$IONS Will this recover to 60? I started doubting 55 now....

0 · Reply

FDALens Jul. 30 at 12:33 AM

$BMY $GILD $IONS $RARE $REPL good luck 🍀

0 · Reply

Market Cap	9.21B
Revenue (ttm)	943.71M
Net Income (ttm)	-381.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-40.41%
Debt to Equity Ratio	0.00

Volume	1,999,600
Avg Vol	3,151,740
Day's Range	N/A - N/A
Shares Out	166.18M
Stochastic %K	82%
Beta	0.41
Analysts	Strong Sell
Price Target	$87.30